Patent intelligence · US
US 11833225
Methods and compositions for efficient gene deletion
Methods and compositions for efficient gene deletion
Patent details — US 11833225
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 5, 2023
- Expiration
- Nov 30, 2043
- Applicant
- CRISPR THERAPEUTICS AG
- Claims
- 21
- CPC classes
- A61K, A61K31/5377, A61K31/7088, A61K35/28
Quick answer
US 11833225 (Methods and compositions for efficient gene deletion) is held by CRISPR THERAPEUTICS AG. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K31/5377, A61K31/7088, A61K35/28, A61K38/465, A61K48/005
More from CRISPR THERAPEUTICS AG
Related pharmaceutical patents in our USPTO index.
-
US 12427170
Universal donor cells
granted -
US 12344656
Genetically engineered T cells having improved persistence in culture
granted -
US 12344655
Gene-edited natural killer cells
granted -
US 12304968
T-cells expressing anti-LIV1 chimeric antigen receptor
granted -
US 12263227
Optimized mRNA encoding CAS9 for use in LNPs
granted -
US 12247201
Materials and methods for treatment of autosomal dominant retinitis pigmentosa
granted -
US 12241087
Compositions and methods for differentiating stem cells into NK cells
granted -
US 12227763
Methods and compositions for treating cancer
granted
Frequently asked questions
What is US patent 11833225?
US 11833225 (Methods and compositions for efficient gene deletion) is held by CRISPR THERAPEUTICS AG. Status: granted. Granted Dec 5, 2023. Expires Nov 30, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11833225?
CRISPR THERAPEUTICS AG is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 65 pharmaceutical patents for this assignee.
When does US 11833225 expire?
Our index shows an expiration date of Nov 30, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.